M-RIZATRIPTAN ODT 10 MG
RIZATRIPTAN (RIZATRIPTAN BENZOATE) : 10 MG · DIN 02548828 · MANTRA PHARMA INC
Health Canada status: MARKETED
What is M-RIZATRIPTAN ODT?
M-RIZATRIPTAN ODT 10 MG contains RIZATRIPTAN (RIZATRIPTAN BENZOATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02548828, held by MANTRA PHARMA INC, supplied as TABLET (ORALLY DISINTEGRATING) for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Jun-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is M-RIZATRIPTAN ODT used for?
Acute treatment of migraine attacks with or without aura in adults. Not for prophylactic therapy or management of hemiplegic, ophthalmoplegic, or basilar migraine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02548828 |
|---|---|
| Brand name | M-RIZATRIPTAN ODT |
| Generic / active ingredient | RIZATRIPTAN (RIZATRIPTAN BENZOATE) : 10 MG |
| Manufacturer | MANTRA PHARMA INC |
| Strength | 10 MG |
| Dosage form | TABLET (ORALLY DISINTEGRATING) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02CC04 RIZATRIPTAN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Jun-2025 |
How is it administered?
Acute treatment: 5 mg or 10 mg. If headache returns, a second dose may be taken after 2 hours. Max 20 mg in 24 hours. Use 5 mg dose if taking propranolol (max 10 mg/24h).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists page 24, but text ends at page 13).
How is it supplied?
Not explicitly detailed in provided text (mentions 5 mg and 10 mg strengths).
Contraindications
Ischemic cardiac, cerebrovascular, or peripheral vascular syndromes; valvular heart disease; arrhythmias; uncontrolled hypertension; severe hepatic impairment; use within 24h of other 5-HT1 agonists.
Warnings and precautions
Risk of myocardial ischemia/infarction. Use only in clear migraine diagnosis. Contains aspartame (phenylalanine). Risk of Serotonin Syndrome. May cause dizziness/somnolence.
What can be used instead?
Other Canadian products sharing ATC code N02CC04 RIZATRIPTAN. 34 of 85 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-RIZATRIPTAN ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | DIN 02483289 |
| ACCEL-RIZATRIPTAN ODT | 5 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | DIN 02483270 |
| ACT RIZATRIPTAN | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02381702 |
| AG-RIZATRIPTAN ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | ANGITA PHARMA INC. | MARKETED | DIN 02492490 |
| AG-RIZATRIPTAN ODT | 5 MG | TABLET (ORALLY DISINTEGRATING) | ANGITA PHARMA INC. | MARKETED | DIN 02492482 |
| APO-RIZATRIPTAN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02393476 |
| APO-RIZATRIPTAN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02393468 |
| JAMP RIZATRIPTAN | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380463 |
| JAMP-RIZATRIPTAN ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | JAMP PHARMA CORPORATION | MARKETED | DIN 02465094 |
| JAMP-RIZATRIPTAN ODT | 5 MG | TABLET (ORALLY DISINTEGRATING) | JAMP PHARMA CORPORATION | MARKETED | DIN 02465086 |
Who else supplies RIZATRIPTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIZATRIPTAN appears in 144 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.